Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UK Accelerated Access Review Can Create A Post-Brexit 'Medtech Powerhouse'

Executive Summary

Medical technology stakeholders in the UK will be poring over the detail of the much-anticipated Accelerated Access Review (AAR), the final report of which was released Oct. 24. The initial response from the industry has been positive.


Related Content

Is The UK Still Open For Medtech Innovation And Reimbursement?
UK Extols NHS Asset In The ‘No Plan B’ Post-Brexit World
Fees Should Be A Last Resort For NICE Funding, Says UK Medtechs
UK Accelerated Access Proposals Due Out Soon